Not provided
Not provided
Not provided
Not provided
inclusion difficulty
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to determine whether the presence of vulnerability detected by geriatricians is associated with treatment discontinuation in older patient. During the comprehensive geriatric assessment realized before the decision-treatment, the following data are recorded and their impact in the therapeutic changes will also be analysed: comorbidity, age, depression, functional status, the cognitive impairment and malnutrition.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| NA/NA | No Intervention |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Vulnerability and therapeutic changes in older patients with multiple myeloma. | Other |
|
| Measure | Description | Time Frame |
|---|---|---|
| The occurrence of the events | The primary outcome is either :
These outcomes will be measured every 6 months during the 2 years of follow up | 6 MONTHS |
| Measure | Description | Time Frame |
|---|---|---|
| Type of Vulnerability | vulnerability related to toxicities, vulnerability related to multiple myeloma or geriatric vulnerability. | 6 MONTHS |
| Therapeutic changes | early interruption of treatment, dose reduction during treatment, discontinuous treatment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Komivi AGBETSIVI, DR | CHD Vendée La Roche sur Yon | Principal Investigator |
| VIGNARD Patricia, Dr | CH du Mans | Principal Investigator |
| Catherine Cattenoz, Dr | Rennes University Hospital | Principal Investigator |
| Jean -Richard EVEILLARD, Dr | CHU de Brest | Principal Investigator |
| François Puisieux, Pr | CHU de Lille | Principal Investigator |
| Jean -Yves NIEMIER, Dr | Central Hospital, Nancy, France | Principal Investigator |
| Frédérique Retornaz, Dr | CGD de Marseille | Principal Investigator |
| Véronique Brunel, Dr | Hôpital Européen de Marseille | Principal Investigator |
| Laure De Decker, Dr | Nantes University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHD Vendée La Roche sur Yon | La Roche-sur-Yon | France | ||||
| CHU de Nantes |
Not provided
| ID | Term |
|---|---|
| D009101 | Multiple Myeloma |
| ID | Term |
|---|---|
| D054219 | Neoplasms, Plasma Cell |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D020141 | Hemostatic Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 6 MONTHS |
| Toxicity during treatment | hematologic toxicity, neurotoxicity, gastrointestinal toxicity, deep vein thrombosis, pulmonary embolism, infections with antibiotic use | 6 months |
| Progression to 1 and 2 years | 1 year/2year |
| Complete response at 1 and 2 years | 1 year/2 years |
| Nantes |
| 44000 |
| France |
| D014652 |
| Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D010265 | Paraproteinemias |
| D001796 | Blood Protein Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006474 | Hemorrhagic Disorders |
| D008232 | Lymphoproliferative Disorders |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |